← Leaderboards
Joseph K. Wong
Veterans Medical Research Fdn/San Diego
$7,004,600
Attributed
$7,962,725
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $840.4K · FY2005–21$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$7,962,725 · 9
VA$0 · 1
By mechanism
R01$4,524,237 · 3
R33$1,366,061 · 1
R56$1,188,457 · 2
R21$848,757 · 2
M01$35,213 · 1
I01$0 · 1
Top collaborators
- Steven A Yukl5 shared
Most similar at Veterans Medical Research Fdn/San Diego
Same institution · by research overlap
- John Guatelli$21,581,148
- Charlotte A Stoneham$644,432
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsBloodVirusViralBaseAntiretroviral TherapyCd4 Positive T LymphocytesIn VivoCellsSamplingCharacteristicsLatent InfectionCessation Of LifePhenotypePlasmaGenetic TranscriptionVariantAntiviral AgentsAffectCardiovascular SystemGut Associated Lymphoid TissueKidneyHepaticLife
Grant awards (28)
Understanding HIV latency reversal and clearance of infected cells in vivo$383,250
R01 · FY2021 · AI
Understanding HIV latency reversal and clearance of infected cells in vivo$383,250
R01 · FY2020 · AI
Understanding HIV latency reversal and clearance of infected cells in vivo$383,250
R01 · FY2019 · AI
Evaluating HIV expression and latency in blood and tissues at the single cell level$447,015
R33 · FY2018 · AI · contact PI
Understanding HIV latency reversal and clearance of infected cells in vivo$383,250
R01 · FY2018 · AI
Evaluating HIV expression and latency in blood and tissues at the single cell level$457,171
R33 · FY2017 · AI · contact PI
Understanding HIV latency reversal and clearance of infected cells in vivo$383,250
R01 · FY2017 · AI
Evaluating HIV expression and latency in blood and tissues at the single cell level$461,875
R33 · FY2016 · AI · contact PI
Tissue Reservoirs of HIV in Victims of Sudden Death$544,989
R56 · FY2015 · AI · contact PI
Evaluating HIV expression and latency in blood and tissues at the single cell level$194,745
R21 · FY2015 · AI · contact PI
Evaluating HIV expression and latency in blood and tissues at the single cell level$246,906
R21 · FY2014 · AI · contact PI
The contribution of Tcell tolerance to latent HIV infection$0
I01 · FY2014 · VA · contact PI
The contribution of Tcell tolerance to latent HIV infection$0
I01 · FY2013 · VA · contact PI
The contribution of Tcell tolerance to latent HIV infection$0
I01 · FY2012 · VA · contact PI
Role of Gut Associated Lymphoid Tissue in HIV Persistence$643,468
R56 · FY2011 · AI · contact PI
The contribution of Tcell tolerance to latent HIV infection$0
I01 · FY2011 · VA · contact PI
HIV-1 Adaptation in the Central Nervous System$354,773
R01 · FY2009 · NS · contact PI
Variation in Neurocognitive Impairment of HIV Ugandan Children by HIV Subtype$173,679
R21 · FY2009 · MH · contact PI
HIV-1 Adaptation in the Central Nervous System$354,773
R01 · FY2008 · NS · contact PI
Variation in Neurocognitive Impairment of HIV Ugandan Children by HIV Subtype$233,427
R21 · FY2008 · MH · contact PI
HIV-1 Adaptation in the Central Nervous System$365,406
R01 · FY2007 · NS · contact PI
HIV-1 Adaptation in the Central Nervous System$376,319
R01 · FY2006 · NS · contact PI
HIV-1 Adaptation in the Central Nervous System$397,725
R01 · FY2005 · NS
VIROLOGIC AND IMMUNOLOGIC EFFECTS OF ADDING ABACAVIR TO HIV PATIENTS$25,813
M01 · FY2005 · RR
VIROLOGIC/IMMUNOLOGIC EFFECT OF ABACAVIR IN HIV PATIENTS$9,400
M01 · FY2004 · RR
IN VIVO HIV LATENCY REVEALED BY POTENT ANTIVIRAL THERAPY$207,512
R01 · FY2002 · AI
IN VIVO HIV LATENCY REVEALED BY POTENT ANTIVIRAL THERAPY$204,331
R01 · FY2001 · AI
IN VIVO HIV LATENCY REVEALED BY POTENT ANTIVIRAL THERAPY$347,148
R01 · FY2000 · AI